Jefferies Downgrades Astria Therapeutics (ATXS) to Hold

Jefferies analyst Eun Yang downgraded Astria Therapeutics (NASDAQ: ATXS) from Buy to Hold with a price target of $13.00 (from $30.00).

For an analyst ratings summary and ratings history on Astria Therapeutics click here. For more ratings news on Astria Therapeutics click here.

Shares of Astria Therapeutics closed at $8.47 yesterday.

You May Also Be Interested In

• Morgan Stanley Downgrades Diamondback Energy (FANG) to Equalweight
• Amer Sports Inc. (AS) PT Lowered to $42 at Truist, but 'Momentum continues to surge in a tough macro'
• Kingsoft Cloud (KC) PT Raised to $21.40 at BofA Securities